Every 10-Q that Alumis Inc (ALMS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow ALMS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ALMS filings page.
Alumis Inc. reported for the quarter and six months ended June 30, 2026 that it remains a clinical-stage biopharma with no product revenue and significant ongoing losses. Total revenue was $1.7 million for the quarter and $3.4 million for the first half of 2026, entirely from collaboration activities with Kaken Pharmaceutical under a license and collaboration agreement.
Operating expenses remain substantial but declined versus 2025. For the first half of 2026, research and development expenses were $166.9 million and general and administrative expenses were $42.0 million, plus a $41.8 million impairment of acquired in-process R&D related to the lonigutamab program after a strategic review. This led to a net loss of $142.2 million for the quarter and $235.3 million year to date, compared with net income in the prior-year quarter that had been driven by a large gain on bargain purchase from the ACELYRIN acquisition.
Liquidity is a key focus. As of June 30, 2026, Alumis held $63.7 million in cash and cash equivalents and $438.6 million in marketable securities, or $502.3 million in total, and stockholders’ equity of $452.2 million. A January 2026 public equity offering provided net proceeds of $323.8 million, and an at-the-market facility allows for up to $300.0 million of additional common stock issuance. The company states this cash balance should fund operations for at least 12 months, but it expects to continue to incur substantial losses and will need significant additional capital to advance its autoimmune pipeline.
Alumis Inc. reports Q1 2026 results showing it remains a clinical-stage company investing heavily in R&D while strengthening its balance sheet. Total revenue was $1.7 million, mainly from collaboration revenue, while net loss narrowed slightly to $93.1 million, or $0.74 per share, versus a $99.0 million loss a year earlier.
R&D expenses were $81.5 million and G&A expenses were $18.6 million, reflecting ongoing development programs and integration of the ACELYRIN merger. Alumis closed a January 2026 public equity offering, receiving $324.4 million in net proceeds, and ended March 31, 2026 with $569.5 million in cash, cash equivalents and marketable securities and total assets of $671.6 million.
The company maintains an accumulated deficit of $994.9 million and continues to expect substantial losses as it develops autoimmune therapies, but believes its current cash resources will fund operating and capital needs for at least 12 months from the financial statement issuance date. An at-the-market facility permits up to $300.0 million in additional stock sales, with no shares sold as of March 31, 2026.
Alumis Inc. reported Q3 2025 results showing a net loss of $110.8 million as R&D spending of $97.8 million and G&A of $19.5 million outweighed $2.1 million of collaboration revenue. For the nine months, total revenue was $22.1 million (license $17.4 million; collaboration $4.7 million), and net loss was $150.4 million, reflecting a $187.9 million gain on bargain purchase from the ACELYRIN merger.
The company completed the ACELYRIN Merger on May 21, 2025, issuing 48,653,549 shares as consideration of $238.1 million for net assets with a fair value of $426.0 million, and recognized a $10.7 million deferred tax liability tied to acquired IPR&D.
As of September 30, 2025, cash and cash equivalents were $65.3 million and marketable securities were $312.5 million; stockholders’ equity was $384.8 million. Operating cash outflow for the nine months was $297.6 million. Management states the $377.7 million in cash, cash equivalents and marketable securities provides at least 12 months of funding. As of November 6, 2025, voting shares outstanding were 97,208,495 and non‑voting shares were 7,184,908.
Alumis Inc. completed the ACELYRIN merger and significantly strengthened its balance sheet. Total assets rose to $610.9 million from $341.0 million at year-end, and combined cash, cash equivalents and marketable securities totaled approximately $486.3 million as of June 30, 2025. The company issued 48,653,549 shares (about $238.1 million consideration) to acquire ACELYRIN, adding the lonigutamab program and an IPR&D intangible asset valued at ~$51.0 million. The acquisition produced a $187.9 million gain on bargain purchase, which turned the quarter to a $59.3 million net income result.
Operationally Alumis remains a development-stage, cash-consuming biopharma. Revenue was $2.7 million for the quarter ($20.1 million six months) while research and development expense rose to $108.8 million in the quarter and operating cash used was $186.7 million for the six months. The company had an accumulated deficit of $698.2 million and states existing resources should fund operations for at least 12 months, though additional capital will be needed thereafter.